vismodegib
Sign in to saveAlso known as GDC-0449, HhAntag691, hedgehog antagonist GDC-0449
Vismodegib, sold under the brand name Erivedge, is a medication used for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma . The drug was developed by the biotechnology/pharmaceutical company Genentech.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 420.01
- Has use
- medication
Show 6 more facts
- chemical formula
- C₁₉H₁₄Cl₂N₂O₃S
- medical condition treated
- basal-cell carcinoma of the skin
- canonical SMILES
- CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
- World Health Organisation international non-proprietary name
- vismodegib
- Commons category
- Vismodegib
- legal status (medicine)
- boxed warning
Sources (8)
via Wikidata · CC0
~2 min read
Encyclopedic overview
7 sectionsContents
- Indication
- Mechanism of action
- Side effects
- Development
- References
- Further reading
- External links
Vismodegib, sold under the brand name Erivedge, is a medication used for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval. The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastoma and chondrosarcoma . The drug was developed by the biotechnology/pharmaceutical company Genentech.
==Indication== Vismodegib is indicated for people with basal-cell carcinoma (BCC) which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.
Excerpted from Wikipedia’s “vismodegib” article, available under the CC BY-SA 4.0 licence.